Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability
Recommendation based on results of Phase 3 CheckMate -9DW clinical trial demonstrating statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib in this patient population
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Exploring new opportunities within the fast-growing market of microfluidics
Acquisition to advance company's next generation biology portfolio with internationally recognized pioneer in organoid development
The new facility marks a significant milestone for Fredun Pharmaceuticals as it expands its footprint in the rapidly growing pet care industry in India
This partnership is set to meet the growing demand for innovative life science research solutions in the Vietnamese market
Launch of new product range aligns with strategy to diversify into emerging applications with high growth potential
Donation drive in São Paulo aims to support 250 young women’s health and environmental responsibility
Subscribe To Our Newsletter & Stay Updated
